RAD December 2020 Abstracts - Page 2


#327 - RNA in situ hybridization permits evaluation of treatment relevant cytokine targets in routine skin biopsies of atopic dermatitis and psoriasis

Alice Wang, Jeffrey M. Cohen, Brett King, William Damsky


#331 - Atopic dermatitis is associated with multiple behavioral problems in United States children

Jaya Manjunath, BS and Jonathan I. Silverberg, MD, PhD, MPH1


#334 - Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Monotherapy, Placebo-controlled Studies (Measure Up 1 and Measure Up 2)

Emma Guttman-Yassky, MD; Henrique D Teixeira, PhD; Eric L Simpson, MD; Kim A Papp, MD; Aileen L Pangan, MD; Andrew Blauvelt, MD; Diamant Thaçi, MD; Chia-Yu Chu, MD; H Chih-ho Hong, MD; Norito Katoh, MD; Amy S Paller, MD; Brian Calimlim, DrPH; Yihua Gu, MS; Xiaofei Hu; PhD; Meng Liu, PhD; Yang, PhD; Allan Raymond Tenorio, MD; Alvina D Chu, MD; Alan D Irvine, MD


#337 - Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies

Kim Papp, MD, PhD, Jacek C. Szepietowski, MD, PhD, Leon Kircik, MD, Darryl Toth, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Kang Sun, PhD, Eric L. Simpson, MD 


#340 - Association of atopic dermatitis with ophthalmologic diseases in hospitalized US adults

M Shaheen, JD, J Silverberg, MD, PhD, MPH


#341 - Early changes in patient-relevant endpoints in three tralokinumab pivotal Phase 3 trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis

Jonathan I. Silverberg, Michael Cork, Andreas Wollenberg, Norito Katoh, Louise Abildgaard Steffensen, Azra Kurbasic, Christina Kurre Olsen, Alexandra Kuznetsova, Marie Louise Østerdal, Andreas Westh Vilsbøll, Mette Deleuran, Eric Simpson 


#342 - Specifically targeting interleukin-13 with tralokinumab improved sleep in two Phase 3, randomised, double-blind, placebo-controlled trials in patients with atopic dermatitis 

Jonathan I. Silverberg, Sébastien Barbarot, Melinda Gooderham, Jan C Simon, Eric Simpson, Azra Kurbasic, Christina Kurre Olsen, Michael J Cork 


#343 - Tralokinumab provides progressive improvements beyond week 16 in patients with atopic dermatitis with an initial partial response

Eric Simpson, Jacob P Thyssen, Carsten Flohr, Norito Katoh, Kim Papp, Louise Abildgaard Steffensen, Bo Bang, Alexandra Kuznetsova, Andrew Blauvelt 


#344 - Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled Phase 3 and Phase 2 trials

Eric Simpson, Joseph F Merola, Jonathan I Silverberg, Rebecca Zachariae, Christina Kurre Olsen, Andreas Wollenberg 


#346 - Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE)

Daniel I. Shrager, Scott Guenthner, David Cohen, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal


© 2020 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.